Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Clinical evidence

RAPIDe-3

92 evidence topics · 15 sources

Objective
Location and study date
Study design
Registry design details
FieldReported value
Other study ID number“PHA022121-C306”
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Crossover Assignment”
Masking“Quadruple”
Eligibility criteria
Treatment
Study outcomes
Rationale for using time to onset of symptom relief by patient global impression of change as the primary endpoint
Key secondary endpoints: registry definitions
Outcome measureMeasure description
“Proportion of study drug-treated attacks achieving PGI-C rating of at least "a little better" at 4 hours post-treatment.”“The PGI-C (7-point scale) is used to evaluate the change in the HAE attack symptoms as compared to pre-treatment.”
“Time to substantial symptom relief, defined as achieving PGI-C rating of at least "better" for 2 consecutive timepoints within 12 hours post-treatment.”“The PGI-C (7-point scale) is used to evaluate the change in the HAE attack symptoms as compared to pre-treatment.”
“Time to substantial symptom relief by Patient Global Impression of Severity (PGI-S).”“Defined as achieving ≥1 point reduction in PGI-S (5-point scale) from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment.”
“Time to complete symptom resolution, defined as achieving PGI-S rating of "none" within 48 hours post-treatment.”“The PGI-S (5-point scale) is used to evaluate the severity of HAE attack symptoms.”
“Time to End of Progression (EoP) in attack symptoms within 12 hours.”“EoP time defined as the earliest post-treatment timepoint after which all subsequent PGI-C ratings are stable or improved.”
“Proportion of study drug-treated attacks requiring rescue medication within 24 hours post-treatment.”“Rescue medication is defined as the participant's usual acute on-demand HAE treatment taken if symptoms persist or progress after study drug administration.”
“Proportion of attacks achieving symptom resolution.”“Defined as achieving PGI-S rating of "none" with one dose of study drug at 24 hours post-treatment.”
“Time to substantial symptom relief by Angioedema Symptom Rating Scale (AMRA).”“Defined as a ≥50% reduction in AMRA composite score from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment.”
“Time to almost complete or complete symptom relief by AMRA.”“Defined as all item scores in AMRA having a value ≤10 for 2 consecutive timepoints within 24 hours post-treatment.”
“Proportion of study drug-treated attacks reaching almost complete or complete symptom relief by AMRA.”“Defined as all item scores in AMRA having a value ≤10 at 24 hours post-treatment.”
“Time to EoP in attack symptoms within 12 hours.”“Defined as the earliest post-treatment timepoint after which every individual AMRA item is stable or improved at all subsequent timepoints.”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
All randomized participants: demographic and disease characteristics, 134 participants
CharacteristicAll randomized participants (N=134)
Age in years, mean (SD)“39.0 (14.7)”
Age ≥12 to <18 years, n (%)“10 (7.5)”
Age ≥18 to <65 years, n (%)“116 (86.6)”
Age ≥65 years, n (%)“8 (6.0)”
Female, n (%)“76 (56.7)”
BMI, mean (SD)“26.5 (5.9)”
White, n (%)“93 (69.4)”
Asian, n (%)“19 (14.2)”
Black or African American, n (%)“10 (7.5)”
Europe, n (%)“56 (41.8)”
Rest of world, n (%)“40 (29.9)”
North America, n (%)“38 (28.4)”
Years since HAE diagnosis, mean (SD)“17.7 (13.0)”
Attacks within 3 months before screening, mean (SD)“4.4 (3.3)”
HAE-C1INH type 1, n (%)“118 (88.1)”
HAE-C1INH type 2, n (%)“10 (7.5)”
Unspecified HAE-C1INH type 1 or 2, n (%)“2 (1.5)”
HAE-nC1INH, n (%)“4 (3.0)”
Current long-term prophylaxis use, n (%)“31 (23.1)”
Participants with at least one treated attack: demographic and disease characteristics by treatment, 113 participants
CharacteristicDeucrictibant (n=101)Placebo (n=100)Overall (n=113)
Age, years, median (IQR)“36·0 (27·0–49·0)”“36·5 (28·0–50·0)”“36·0 (27·0–50·0)”
Male“46 (46%)”“46 (46%)”“51 (45%)”
Female“55 (54%)”“54 (54%)”“62 (55%)”
White“70 (69%)”“70 (70%)”“80 (71%)”
Asian“17 (17%)”“16 (16%)”“17 (15%)”
Black or African American“4 (4%)”“6 (6%)”“6 (5%)”
North America“21 (21%)”“26 (26%)”“28 (25%)”
Europe“47 (47%)”“41 (41%)”“50 (44%)”
Rest of world“33 (33%)”“33 (33%)”“35 (31%)”
BMI, kg/m2, median (IQR)“25·2 (22·3–28·2)”“25·6 (22·5–29·2)”“25·5 (22·4–28·9)”
HAE-C1INH-type 1“90 (89%)”“91 (91%)”“102 (90%)”
HAE-C1INH-type 2“8 (8%)”“8 (8%)”“8 (7%)”
HAE-nC1INH“2 (2%)”“0”“2 (2%)”
Unspecified HAE-C1INH type 1 or 2“1 (1%)”“1 (1%)”“1 (1%)”
Time since diagnosis, years, median (IQR)“15·0 (7·0–24·0)”“15·5 (7·0–24·5)”“15·0 (7·0–24·0)”
Concomitant long-term prophylaxis: yes“20 (20%)”“24 (24%)”“26 (23%)”
Long-term prophylaxis: lanadelumab“8 (8%)”“10 (10%)”“11 (10%)”
Long-term prophylaxis: berotralstat“5 (5%)”“7 (7%)”“7 (6%)”
Long-term prophylaxis: C1-esterase inhibitor“4 (4%)”“5 (5%)”“5 (4%)”
Long-term prophylaxis: danazol“3 (3%)”“2 (2%)”“3 (3%)”
Attacks in the 3 months before screening: 2–5“72 (71%)”“71 (71%)”“83 (73%)”
Attacks in the 3 months before screening: 6–10“19 (19%)”“19 (19%)”“20 (18%)”
Attacks in the 3 months before screening: 11–15“6 (6%)”“6 (6%)”“6 (5%)”
Attacks in the 3 months before screening: 16–20“2 (2%)”“2 (2%)”“2 (2%)”
Primary efficacy analysis set: demographic and disease characteristics, 88 participants
CharacteristicPrimary efficacy analysis group (N=88)
Age in years, mean (SD)“38.7 (13.6)”
Age ≥12 to <18 years, n (%)“5 (5.7)”
Age ≥18 to <65 years, n (%)“80 (90.9)”
Age ≥65 years, n (%)“3 (3.4)”
Female, n (%)“47 (53.4)”
North America, n (%)“19 (21.6)”
Europe, n (%)“38 (43.2)”
Rest of world, n (%)“31 (35.2)”
Years since HAE diagnosis, mean (SD)“17.3 (12.24)”
HAE-C1INH type 1, n (%)“79 (89.8)”
HAE-C1INH type 2, n (%)“8 (9.1)”
Unspecified HAE-C1INH type 1 or 2, n (%)“1 (1.1)”
Current long-term prophylaxis use, n (%)“18 (20.5)”
Efficacy results
Primary and secondary endpoints by PGI-C and PGI-S, primary efficacy analysis set of 88 participants with paired attacks
Endpoint and statisticDeucrictibant N'Deucrictibant resultPlacebo N'Placebo resultp value
Primary: time to onset of symptom relief (PGI-C), median time (95% CI), h“83/88”“1·28 (1·05 to 1·52)”“87/88”“>12 (5·82 to >12)”“<0·0001”
Attacks meeting onset of symptom relief at 4 hours (PGI-C), n (%)“83/88”“69/83 (83%)”“87/88”“24/87 (28%)”“<0·0001”
Time to substantial symptom relief (PGI-C), median time (95% CI), h“83/88”“2·85 (2·08 to 3·35)”“87/88”“>12 (10·30 to >12)”“<0·0001”
Time to reduction in attack severity (PGI-S), median time (95% CI), h“83/88”“2·41 (1·70 to 2·98)”“84/88”“>12 (12·34 to >12)”“<0·0001”
Time to complete symptom resolution (PGI-S), median time (95% CI), h“83/88”“11·95 (8·61 to 21·79)”“87/88”“>48 (>48 to >48)”“<0·0001”
Time to end of progression (PGI-C), median time (95% CI), min“83/88”“17·47 (16·27 to 19·17)”“87/88”“228·67 (61·82 to 599·60)”“<0·0001”
Complete symptom resolution with one dose at 24 hours (PGI-S), n (%)“83/88”“50/83 (60%)”“87/88”“13/88 (15%)”“<0·0001”
Regional subgroups, North America and Europe or rest of world: all participants with treated attacks
Region and endpointDeucrictibantPlacebo
North America: time to onset of symptom relief, median“1.20 hours (95% CI: 0.84, 1.84)”“6.55 hours (95% CI: 1.88, >12)”
Europe/Rest of World: time to onset of symptom relief, median“1.28 hours (95% CI: 1.04, 1.41)”“>12 hours (95% CI: 5.74, >12)”
North America: time to reduction in attack severity, median“2.43 hours (95% CI: 1.03, 5.12)”“>12 hours (95% CI: 2.65, >12)”
Europe/Rest of World: time to reduction in attack severity, median“2.53 hours (95% CI: 1.70, 2.98)”“>12 hours (95% CI: 12.10, >12)”
North America: time to complete symptom resolution, median“11.61 hours (95% CI: 2.94, 26.14)”“>48 hours (95% CI: 17.21, >48)”
Europe/Rest of World: time to complete symptom resolution, median“12.04 hours (95% CI: 8.64, 21.79)”“>48 hours (95% CI: >48, >48)”
North America: onset of symptom relief at 4 hours“77.8% (n=14/18)”“46.2% (n=12/26)”
Europe/Rest of World: onset of symptom relief at 4 hours“84.6% (n=66/78)”“26.4% (n=19/72)”
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events, safety analysis set
Event categoryNon-attack deucrictibant (n=10): participants, n (%)Non-attack: events, nTreated attack deucrictibant (n=100): participants, n (%)Deucrictibant: events, nTreated attack placebo (n=101): participants, n (%)Placebo: events, n
Any treatment-emergent adverse event“3 (30%)”“4”“24 (24%)”“40”“17 (17%)”“22”
Any treatment-emergent adverse event related to study drug“0”“0”“5 (5%)”“6”“1 (1%)”“1”
Any serious treatment-emergent adverse event“0”“0”“1 (1%)”“1”“1 (1%)”“1”
Any serious treatment-emergent adverse event related to study drug“0”“0”“0”“0”“0”“0”
Any severe treatment-emergent adverse event“0”“0”“1 (1%)”“2”“1 (1%)”“3”
Any severe treatment-emergent adverse event related to study drug“0”“0”“0”“0”“0”“0”
Any treatment-emergent adverse event within 3 days post-treatment“0”“0”“15 (15%)”“17”“2 (2%)”“3”
Treatment-emergent adverse event within 3 days related to study drug“0”“0”“5 (5%)”“6”“1 (1%)”“1”
Any serious treatment-emergent adverse event within 3 days post-treatment“0”“0”“0”“0”“0”“0”
Any severe treatment-emergent adverse event within 3 days post-treatment“0”“0”“0”“0”“0”“0”
Treatment-emergent adverse event leading to trial or study drug discontinuation“0”“0”“0”“0”“0”“0”
Treatment-emergent adverse event leading to death“0”“0”“0”“0”“0”“0”
Fatigue within 3 days post-treatment“0”“0”“2 (2%)”“2”“0”“0”
Maximum severity grade of treatment-emergent adverse events, safety analysis set
Participants with ≥1 TEAE by maximum gradePlacebo (N=101)Deucrictibant (N=100)
Any TEAEs“17 (16.8)”“24 (24.0)”
Maximum Grade 1 (Mild)“10 (9.9)”“13 (13.0)”
Maximum Grade 2 (Moderate)“6 (5.9)”“10 (10.0)”
Maximum Grade 3 (Severe)“0”“1 (1.0)”
Maximum Grade 4 (Life-threatening)“1 (1.0)”“0”
Maximum Grade 5 (Fatal)“0”“0”
Study limitations
Summary
  • The authors stated that “Limitations of this trial include the lack of attack stratification according to location and severity”, and that a larger proportion of severe attacks was therefore observed in the placebo group: severe or very severe attacks at pre-treatment were 17 (17%) of 101 deucrictibant-treated and 29 (29%) of 100 placebo-treated attacks. Two non-severe laryngeal attacks were treated with deucrictibant and none with placebo.
  • Severe laryngeal attacks were not included, because of the risks of random assignment to double-masked placebo, and adolescents were instructed to treat laryngeal attacks of any severity with conventional on-demand therapy.
  • The sponsor ended the trial after the prespecified number of participants with paired attacks was reached and before all participants had treated two attacks. Of 134 enrolled participants, 113 treated at least one attack and 88 contributed paired attacks to the primary efficacy analysis. One participant randomized to the deucrictibant-placebo sequence was given placebo in error and treated no second attack.
  • Each participant treated at most one attack with deucrictibant in the crossover, and safety comparisons were descriptive. Treatment-emergent adverse events within 3 days of study drug were considered temporally clinically relevant.
  • Subgroups were small: ten (7%) enrolled participants were adolescents, five of them in the primary efficacy analysis set, and only two unpaired attacks were recorded in participants with hereditary angioedema with normal C1 inhibitor.
  • Eligibility required experience effectively using conventional on-demand therapy and excluded people older than 75 years, people with abnormal hepatic function or eGFR <60 ml/min/1.73 m2, users of strong CYP3A4 inhibitors or inducers, people with prior gene therapy, and pregnant or breastfeeding women.
  • Use of rescue or selected prohibited medication was counted as treatment failure, and missing data at the end of follow-up were handled by right censoring without imputation.
  • Health-related quality of life outcomes were exploratory endpoints planned for separate publication.